Medical Policy: 02.04.74 

Original Effective Date: August 2018 

Reviewed: August 2018 

Revised:  

 

Benefit Application:

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

 

This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.

 

Description:

This policy focuses on testing of BRCA mutation status. This testing may be completed as a test for cancer susceptibility or in tumor/tissue of an individual with a current cancer diagnosis.

 

BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged DNA and, therefore, play a role in ensuring the stability of each cell’s genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer.

 

Harmful BRCA1 and BRCA2 gene mutations are relatively rare in the general population, most experts agree that mutation testing of individuals who do not have cancer should be performed only when the person’s individual or family history suggests the possible presence of a harmful mutation in BRCA1 or BRCA2. Genetic testing is only recommended for people with a high risk of having a BRCA mutation.

 

Prostate Cancer

Patients with BRCA variants have an increased risk of prostate cancer, and patients with known BRCA variants may, therefore, consider more aggressive screening approaches for prostate cancer. However, the presence of prostate cancer in an individual, or in a family, is not itself considered sufficient justification for BRCA testing.

 

PracticeGuidelines and Position Statements

National Comprehensive Cancer Network (NCCN)

National Comprehensive Cancer Network (NCCN) guidelines present specific criteria for genetic testing for hereditary breast and/or ovarian cancer syndrome. The guidelines address genetic risk assessment, counseling, testing and management based on test results.

 

The current National Comprehensive Cancer Network (NCCN) guideline (Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 1.2019) states that a male warrants genetic counseling and to consider genetic testing if he has prostate cancer of Gleason score 7 or higher and one of the following: (1) at least one close blood relative with ovarian cancer or breast cancer at age 50 or younger, or (2) at least two relatives with breast, ovarian, or prostate cancers (Gleason 7 or higher) at any age. Testing with a diagnosis of prostate cancer without the family history component is not recommended.

 

At this time no other NCCN guidelines recommend the genetic testing of BRCA1 or BRCA2 based on diagnosis alone.

 

American Society of Clinical Oncology (ASCO)

An ASCO policy statement recommends that genetic testing for cancer susceptibility be performed when the following three criteria are met: the individual being tested has a personal or family history suggestive of genetic cancer susceptibility; the test can be adequately interpreted; and the test results have accepted clinical utility.

 

United States Preventative Services Task Force (USPSTF)

Current USPSTF guidelines recommend screening women with any family history of breast, ovarian, tubal, or peritoneal cancer. Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing. (Grade B Recommendation; Recommended). USPSTF recommends against routine genetic counseling or BRCA testing for those whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1or BRCA2 gene. (Grade D recommendation; Not recommended).

 

Professional societies do not recommend that children under age 18, even those with a family history suggestive of a harmful BRCA1 or BRCA2 mutation, undergo genetic testing for BRCA1 or BRCA2 This is because there are no risk-reduction strategies that are specifically meant for children, and children's risks of developing a cancer type associated with a BRCA1 or BRCA2 mutation are extremely low.

 

Prior Approval:

Prior Approval is required.

 

Policy:

Genetic testing of BRCA1 and BRCA2 for breast cancer, ovarian cancers, hereditary breast and ovarian cancer syndrome (HBOC) or in those with Ashkenazi Jewish ethnicity is not addressed in this policy.

 

For additional information see the following policies.

 

For panel testing for inherited cancer susceptibility see policy: Expanded Genetic Panels to Identify Cancer Risk 02.04.64

 

For panel testing of an individual with a cancer diagnosis see policy: Expanded Genetic Panels to Identify Targeted Cancer Therapy 02.04.63

 

Genetic testing for BRCA mutation/variants for all other indications, including but not limited to the following, is considered investigational.

  • Gastrointestinal Cancers
  • Laryngeal Cancer
  • Lynch Syndrome
  • Melanoma
  • Myeloproliferative disease
  • Prostate Cancer
  • Pancreatic Cancer
  • Blood Cancers

 

Further evidence is needed to establish the clinical utility of testing in populations outside of indications for breast cancer, ovarian cancers, Ashkenazi Jewish ethnicity, and HBOC risk. Tests are frequently conducted solely as informational, this will not alter medical management of the patient therefore testing currently lacks clinical utility and does not demonstrate improved net health outcomes. The outcome of the test must be expected to determine a covered course of treatment.

 

Procedure Codes and Billing Guidelines:

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes and / or diagnosis codes.

  • 81162 BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis
  • 81163 BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
  • 81164 BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
  • 81165 BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
  • 81166 BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
  • 81167 BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
  • 81212 BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants
  • 81215 BRCA1 (BRCA1, DNA repari associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
  • 81216 BRCA2 (BRCA2, DNA repari associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis 
  • 81217 BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
  • 81432 Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53
  • 81433 Hereditary breast cancer-related disorders (e.g., hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11

 

Selected References:

  • Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D, Collaborators UKGPCS, Goldgar D, Eeles R, Kote-Jarai Z. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106:1697–701.
  • Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16:2115–21.
  • Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2016 Dec 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.  
  • Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. Oct 24 1998;352(9137):1337-1339. PMID 9802270
  • Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. Jan 2015;136(1):3-7. PMID 25238946
  • Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. Feb 18 2014;160(4):271-281. PMID 24366376
  • NCCN Guideline Genetic/Familial High-Risk Assessment: Colorectal Version 01.2018  
  • NCCN Guideline Prostate Cancer Version 03.2018 
  • NCCN Guideline Genetic/Familial High-Risk Assessment: Prostate Cancer Early Detection Version 02.2018 
  • NCCN Guideline Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 01.2019 
  • NCCN Guideline Pancreatic Adenocarcinoma Version 02.2018  
  • NCCN Guideline Melanoma 03.2018  
  • NCCN Guideline Myeloproliferative Neoplasms Version 02.2018 
  • National Institute for Health and Care Excellence (NICE). (June, 2013 last update March 2017). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. 
  • National Cancer Institute (2018) BRCA Mutations: Cancer Risk and Genetic Testing. 
  • ECRI Institute. Genetic testing for BRCA1 and BRCA2 Mutations for Assessing Pancreatic Cancer Risk. Plymouth Meeting (PA): ECRI Institute; 2010 Dec 9. 7p. [ECRI hotline response].

 

 

Policy History:

  • August 2018 - New Policy

Wellmark medical policies address the complex issue of technology assessment of new and emerging treatments, devices, drugs, etc.   They are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. Wellmark medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Wellmark does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Wellmark or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies may be updated and therefore are subject to change without notice.

 

*CPT® is a registered trademark of the American Medical Association.